



Catalog Number: PR15046CF

Product Type: Recombinant Protein

Source: Murine myeloma cell line, NS0 derived

Description/Molecular Mass: Pro22 Gln291 Accession # Q6PE62. N-Terminal= Pro22. Predicted Molecular Mass: 29.4 kDa

SDS PAGE: 40 50 kDa, reducing conditions

Activity: Measured by its ability to inhibit the biological activity of IGFI or IGFI on MCF7 human breast adenocarcinoma cells. Karey, K.P. et al. (1988) Cancer Research 48:4083. The ED₅₀ for this effect is typically 0.125 0.5 µg/mL in the presence of 30 ng/mL rIGFI.

Endotoxin Level: <1.0 EU per 1 µg of the protein by the LAL method.

Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Format: Lyophilized from a 0.2 µm filtered solution in Acetonitrile and TFA. See Certificate of Analysis for details.

Reconstitution: Reconstitute at 100 µg/mL in sterile PBS.

Storage: 12 months from date of receipt, 20 to 70°C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
3 months, 20 to 70 °C under sterile conditions after reconstitution.
Avoid multiple freeze-thaw cycles.

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. V3-01/13

www.neuromics.com

Neuromics • 5325 West 74th Street, Suite 8 • Edina, MN 55439
phone 866-350-1500 • fax 612-677-3976 • e-mail pshuster@neuromics.com